We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Released on Friday, February 7, the January jobs report showed resilience in the labor market with higher-than-expected wage ...

Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Inspire Medical shares dipped — but have since mostly recovered — following news of a government investigation following Q4 ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Doctors have begun noticing a trend among their colleagues: many have visibly shed pounds, and it's all thanks to drugs like ...